Pharmaxis concludes Brochitol trial
Friday, 13 June, 2008
Pharmaxis (ASX:PXS) has completed a Phase III clinical trial of its Bronchitol inhalant spray for bronchiectasis.
The 12-month trial was an open label extension to an earlier efficacy trial and was designed to determine the adverse event profile of Bronchitol following prolonged use.
Bronchiectasis is an incurable and chronic lung condition which causes excessive mucus to build up in the lungs, making breathing difficult.
Pharmaxis intends to file a marketing application for Bronchitol after the results are published in July.
Organoid platform enables closer study of bat-borne viruses
Reconstructing bat organ physiology in the lab lets scientists explore how zoonotic viruses work...
Global study finds 250 genes linked to OCD
Researchers say they have found the genes linked to obsessive compulsive disorder (OCD), after...
TGA approves therapy for paediatric growth hormone deficiency
The TGA has approved SKYTROFA as a treatment for growth failure in children and adolescents aged...
